The safety and efficacy of N9-GP (nonacog beta pegol; Novo Nordisk A/S, Bagsværd, Denmark), a recombinant glycoPEGylated factor IX (FIX) with extended half-life (EHL),[@CIT0001] was investigated in the multinational, Phase 3, paradigm 2 trial (NCT01333111), previously reported by Collins et al in *Blood*.[@CIT0002] The trial was conducted in accordance with the Declaration of Helsinki and written informed consent was provided by all participants. Prior to trial initiation, the protocol, the protocol amendments, the consent form, and the patient information sheet were reviewed and approved according to local regulations by appropriate health authorities and by independent ethics committees/institutional review boards (see [Table S1](#ST0001)). Patients 13--70 years of age with previously treated hemophilia B (≤2% baseline FIX) were allocated to either once-weekly prophylaxis or on-demand (OD) treatment. The OD treatment was a US Food and Drug Administration requirement prior to enrolling patients on prophylaxis in the USA.

While much of the focus on EHL FIX products has been around prophylaxis, some patients with severe hemophilia, and the majority with mild/moderate hemophilia, are treated OD. Recent epidemiologic studies have demonstrated that patients with FIX levels up to 15--20% may experience bleeding.[@CIT0003],[@CIT0004] Thus, renewed interest in the potential use of N9-GP as a single-dose OD treatment prompted a post hoc patient-level analysis from the paradigm 2 trial to describe the dosing and efficacy of N9-GP as an OD treatment.

Fifteen of 74 patients in paradigm 2 were enrolled to OD treatment, consisting of a single 40-IU/kg dose of N9-GP, with additional doses of 40 IU/kg as required. Thirteen patients (86.7%) had severe hemophilia (FIX \<1 IU/dL) and 2 (13.3%) had moderate hemophilia (FIX 1--2 IU/dL). Twelve patients (80.0%) had target joint (TJ) bleeds at baseline. The study duration of OD treatment in paradigm 2 was 28 weeks.

Fourteen patients reported 143 bleeds, all mild/moderate in severity ([Table 1](#T0001){ref-type="table"}). Most bleeds (83.9%) were treated with a single dose of N9-GP, and the remainder with 2 or more doses ([Table 1](#T0001){ref-type="table"}). Considering patient-level data, seven patients had all 62 of their bleeds (100%) treated with 1 dose. Annualized bleeding rates in these patients were reduced by 37% from 26.1 prestudy to 16.5 on-study. Hemostatic response was rated excellent for 36 and good for 26 bleeds.Table 1OD treatment of bleeds by the number of N9-GP dosesOD treatment arm (N=15)Number of patientsNumber of bleedsPatients with no bleeds10All patients with bleeds14143 Bleeds treated with only 1 dose13120 (83.9%) Bleeds treated with 2 or more doses723 (16.1%)Patients with only 1-dose treated bleeds762Patients with at least one bleed treated with 2 or more doses781 Bleeds treated with only 1 dose58 (71.6%) Bleeds treated with 2 or more doses23 (28.4%) Patients with recurrent TJ bleeds211  Bleeds treated with only 1 dose7 (63.6%)  Bleeds treated with 2 or more doses4 (36.4%) Patients with other bleeds570  Bleeds treated with only 1 dose51 (72.9%)  Bleeds treated with 2 or more doses19 (27.1%)[^1]

The other seven patients had at least one bleed treated with 2 or more doses of N9-GP. While 28.4% of their bleeds were treated with 2 or more doses (hemostatic response: 18, good; 5, moderate), 71.6% were still treated with only 1 dose (hemostatic response: 7, excellent; 49, good; 1, moderate; 1, not reported).

Two of the 7 patients experienced 11 recurrent TJ bleeds, 4 (36.4%) of which required treatment with 2 or more doses of N9-GP. One patient, 18 years of age, reported three elbow TJ bleeds in 2 months, which were treated with 1, 5, and 2 doses of N9-GP, respectively. The second patient, 27 years of age, was treated prophylactically with plasma-derived FIX (pdFIX) 100 IU/kg every 3 days prior to entering the OD arm of paradigm 2. He reported two bleeds in 2 weeks in his right ankle TJ; one TJ bleed was treated with 2 doses (1 for early rebleeding) and the second bleed was treated with 6 doses, after which the patient was withdrawn.

The other 5 of the 7 patients experienced 70 bleeds; 72.9% were treated with 1 dose (hemostatic response: 2, excellent; 47, good; 1, moderate; 1, not reported) and 27.1% with 2 or more doses (hemostatic response: 17, good; 2, moderate). Four of these five patients had previously received 2 or 3 high FIX doses (60--81 IU/kg) for treating a bleed before entering the study and reported 63 bleeds while on study, which accounted for 44% of all bleeds in the OD treatment arm ([Figure 1](#F0001){ref-type="fig"}). The average N9-GP dose in these four patients ranged from 41.7 to 71.1 IU/kg per bleed and FIX utilization was reduced by 56--80% compared with the patient's historical FIX utilization ([Figure 1](#F0001){ref-type="fig"}). The fifth patient was treated prestudy with 1 prescribed infusion of 34 IU/kg pdFIX per bleed with unknown effectiveness and had seven bleeds while on study (6 treated with 1 dose of \~40 IU/kg per protocol and 1 with 2 doses; mean 46.8 IU/kg per bleed).Figure 1Treatment of patients with a history of requiring multiple high-dose FIX.**Abbreviations:** FIX, factor IX; pdFIX, plasma-derived factor IX; rFIX, recombinant factor IX.

This post hoc analysis from paradigm 2 supports an important potential role for N9-GP in the OD treatment of mild/moderate bleeds. Modeling based upon the Phase 1 pharmacokinetic study to achieve recommended FIX levels suggested by the World Federation of Hemophilia[@CIT0001],[@CIT0005] indicated that N9-GP could potentially reduce the number of doses and total FIX utilization compared with recombinant FIX (rFIX) or pdFIX: 1 vs 2 doses for mild/moderate bleeds (40 vs 95--110 IU/kg), 1 vs 6 doses for severe bleeds (80 vs 310--350 IU/kg), and 5 vs 28 doses for intracranial hemorrhage (240 vs 1450--1490 IU/kg).[@CIT0006]

The recent Bridging Hemophilia Experiences Results and Opportunities into Solutions (B-HERO-S) study in patients with mild-moderate-severe hemophilia in the USA reported that increasing education about self‐infusion may be of benefit to individuals, particularly those with mild/moderate hemophilia: treatment is typically given at a hemophilia clinic or hospital and/or patients need assistance from family members or health care professionals; fewer than 10% of patients reported that all their infusions were at home.[@CIT0007] Delays in recognizing bleeds or receiving help with infusions may also impact outcomes over time. Specifically, B-HERO-S showed that pain, functional impairment, and anxiety/depression were present at higher-than-expected levels in patients with mild/moderate hemophilia B, including affected women, suggesting unmet needs in the management of this population and perhaps undertreatment of bleeding episodes.[@CIT0008] Coupled with improved education to increase the recognition of bleeds, the ability to treat most bleeds with 1 dose with sustained FIX activity, within the World Federation of Hemophilia guidelines[@CIT0005] recommendations over many days, offers a potential pathway to improved outcomes.

In conclusion, a single 40 IU/kg dose of N9-GP was effective as an OD treatment for most bleeds in patients with hemophilia B investigated in paradigm 2. For patients who required additional N9-GP doses, the majority had either recurrent TJ bleeds or a history of multiple high-dose treatment. A prolonged duration of treatment after bleeding and potential change to routine prophylaxis is typical for patients with recurrent TJ bleeds. For patients who may not have required additional dosing of rFIX/pdFIX based upon their phenotype or individual pharmacokinetics, the paradigm 2 analysis supports the predictive modeling that a change to N9-GP would likely be associated with fewer infusions and FIX utilization than rFIX/pdFIX.
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Table S1List of independent ethics committees or institutional review boards that approved the paradigm 2 trial (NCT01333111)CountryIndependent ethics committee/institutional review board**Germany**Ethikkommission\
Medizinsche Hochschule Hannover\
Carl-Neuberg-Straße 1\
30625 Hannover**France**Comité de Protection des Personnes - Sud Est III\
Hôpital Edouard Herriot\
5 Place d'Arsonval\
69003 LYON**Italy**Segreteria Comitato Etico\
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico\
Via F.Sforza, 28\
20122 MilanoComitato Etico per la Sperimentazione Clinica dei Medicinali dell'Azienda Ospedaliero-Universitaria-Careggi\
Via Pieraccini, 17\
50139 Firenze**Japan**IRB of Nara Medical University Hospital\
840 Shijo-cho, Kashihara-shi,\
Nara, 634-8522IRB of Nagoya University Hospital\
65 Tsurumai-cho, Showa-ku, Nagoya-shi,\
Aichi, 466-8560IRB of Hyogo College of Medicine Hospital\
1-1 Mukogawa-Cho, Nishinomiya-shi,\
Hyogo, 663-8501IRB of Ogikubo Hospital\
3-1-24,Imagawa, Suginamiku,\
Tokyo, 167-0035IRB of Tokyo Medical University Hospital\
6-7-1 Nishishinjuku, Shinjukuku,\
Tokyo, 160-0023IRB of St. Marianna University School of Medicine Hospital\
2-16-1 Sugao Miyamae-ku,\
Kawasaki-shi, Kanagawa, 216-8511**Macedonia**Ethic Committee for investigations in people\
50 divizija Skopje\
Macedonia**Malaysia**Medical Research & Ethics Committee, National Institute of Health D/A Institute Pengurusan Kesihatan\
Jalan Rumah Sakit, Bangsar\
59000 Kuala Lumpur**Netherlands**UMCU\
Heidelberglaan 100\
3584 CX Utrecht**Russia**Ethic Committee at Ministry of Health and Social Development of Russian Federation\
3, Rahmanovsky pereulok\
Moscow, 127994**Thailand**Committee on Human Right Related to Research Involving Human Subjects Faculty of Medicine,\
Ramathibodi Hospital Mahidol University\
270 Rama VI Road, Ratchathewi,\
Bangkok 10400**Turkey**Erciyes University Clinical Trials Ethics Committee\
Erciyes University Deanship of\
Medical Faculty Melikgazi/KAYSERI**United Kingdom**Berkshire REC South West REC Centre\
South West REC Centre\
Level 3 Block B\
Whitefriars\
Lewins Mead\
Bristol, BS1 2NTOxford Radcliffe Hospitals NHS Trust\
Research & Development Department\
Manor House\
The John Radcliffe Hospital\
Headington\
Oxford, OX3 9DZThe Joint Clinical Trials Office\
16th Floor Tower Wing,\
Guy's Hospital,\
Great Maze Pond, SE1 9RTRoyal Free Hampstead NHS Trust\
Research & Development\
Royal Free Hospital\
Pond Street\
London, NW3 2QGCardiff and Vale University Local Health Board\
Health Board\
Second Floor, Tower Block Two, Room 3\
University Hospital of Wales\
Heath Park\
Cardiff, CF14 4XNHampshire Hospitals NHS Foundation Trust\
Research & Development,\
Rm 32, F Floor\
Aldermaston Road\
Basingstoke, RG24 9NA**United States**Western Institutional Review Board\
3535 7th Avenue SW\
Olympia, WA 98502-5010Johns Hopkins University\
1620 McElderry Street\
Reed Hall, Suite B-130\
Baltimore, MD 2105Mount Sinai Hospital\
Program for Protection of Human Subjects\
One Gustave L. Levy Place, Box 1075\
New York, NY 10029The Pennsylvania State University College of Medicine\
Human Subjects Protection Office\
Penn State College of Medicine\
600 Centerview Drive, Mail Code A115\
Hershey, PA 17033Children's Hospitals and Clinics of Minnesota\
280 North Smith Avenue\
Suite 4-200\
Minneapolis, MN 55102Texas Children's Hospital\
One Baylor Plaza, 600D\
Houston, TX 77030University of Nebraska Medical Center\
Joint Pediatric Institutional Review Board\
987830 Nebraska Medical Center\
Omaha, NE 68198-7830Chesapeake Research Review Inc\
7063 Columbia Gateway Drive\
Suite 110\
Columbia, MD 21046Children's Hospital Los Angeles Committee on Clinical Investigations Human Subjects Protection Program\
4551 Sunset Blvd., MS 23\
Los Angeles, CA 90027Nemours Children's Clinic Nemours Florida Institutional Review Board\
807 Children's Way\
Jacksonville, FL 32207St. Michael's Medical Center IRB\
111 Central Avenue\
Newark, NJ 07102The Gulf States Hemophilia & Thrombophilia Center Committee for the Protection of Human Subjects\
6410 Fannin Street, Suite 1100SUNY Upstate Medical University IRB for the Protection of Human Subjects\
750 East Adams Street\
1109 WSK Hall\
Syracuse, NY 13210**Zambia**Wits Health Consortium (Pty) Ltd\
8 Blackwood Avenue\
Parktown, Gauteng 2193\
South Africa

[^1]: **Abbreviations:** N, number of patients; OD, on-demand; TJ, target joint.
